Backs prior FY24 reveue view $2.7B- $2.B, consensus $2.77B…In connection with a presentation to be made at an investor conference on January 15, Amneal Pharmaceuticals (AMRX) intends to announce that it expects to meet or exceed its 2024 full year financial guidance. This guidance was announced on November 8 during the Company’s third quarter investor call. The Company expects to meet its net revenue, adjusted EBITDA, and adjusted diluted EPS guidance, exceed its operating cash flow guidance, and exceed its capital expenditures guidance. The Company also intends to announce that it estimates its net leverage as of December 31, 2024 to be approximately 4x. this information was taken from a company 8K filing.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.